Abstract
Background: Triple-Negative Breast Cancer is an aggressive type of breast cancer, which is not treatable by chemotherapy drugs, due to the lack of Estrogen Receptor (ER), Progesterone Receptor (PR) expression and Human Epidermal Growth Factor Receptor 2 (HER2) on the cell surface.
Objective: The aim of this study was to compare the effect of paclitaxel loaded PLGA nanoparticle (PTX-NPs) on the cytotoxicity and apoptosis of the different MDA-MB type of cell lines.
Method: PTX-NPs were prepared by nanoprecipitation method and characterized earlier. The cytotoxicity of PTX-NPs was evaluated by MTT and LDH assay, later apoptosis was calculated by flow cytometry analysis.
Results: The prepared NP size of 317.5 nm and zetapontial of -12.7 mV showed drug release of 89.1 % at 48 h. MDA-MB-231 type cell showed significant cytotoxicity by MTT method of 47.4 ± 1.2 % at 24 h, 34.6 ± 0.8 % at 48 h and 23.5 ± 0.5 % at 72 h and LDH method of 35.9 ± 1.5 % at 24 h, 25.4 ± 0.6 % at 48 h and 19.8 ± 2.2 % at 72 h with apoptosis of 47.3 ± 0.4 %.
Conclusion: We have found that PTX-NPs showed the cytotoxic effect on all the MDA-MB cancer cell lines and showed potent anticancer activities against MDA-MB-231 cell line via induction of apoptosis.
Keywords: MDA-MB, cell lines, paclitaxel, nanoparticle, apoptosis, anticancer.
Current Pharmaceutical Design
Title:Effect of Paclitaxel-Loaded PLGA Nanoparticles on MDA-MB Type Cell Lines: Apoptosis and Cytotoxicity Studies
Volume: 24 Issue: 28
Author(s): Venugopal Vijayan*, Krishnan Shalini, V. Yugesvaran, Teh Hui Yee, Siventhiran Balakrishnan and Vasanth Raj Palanimuthu
Affiliation:
- Faculty of Pharmacy, Asian Institute of Medical Science and Technology (AIMST) University, Bedong 08100, Kedah,Malaysia
Keywords: MDA-MB, cell lines, paclitaxel, nanoparticle, apoptosis, anticancer.
Abstract: Background: Triple-Negative Breast Cancer is an aggressive type of breast cancer, which is not treatable by chemotherapy drugs, due to the lack of Estrogen Receptor (ER), Progesterone Receptor (PR) expression and Human Epidermal Growth Factor Receptor 2 (HER2) on the cell surface.
Objective: The aim of this study was to compare the effect of paclitaxel loaded PLGA nanoparticle (PTX-NPs) on the cytotoxicity and apoptosis of the different MDA-MB type of cell lines.
Method: PTX-NPs were prepared by nanoprecipitation method and characterized earlier. The cytotoxicity of PTX-NPs was evaluated by MTT and LDH assay, later apoptosis was calculated by flow cytometry analysis.
Results: The prepared NP size of 317.5 nm and zetapontial of -12.7 mV showed drug release of 89.1 % at 48 h. MDA-MB-231 type cell showed significant cytotoxicity by MTT method of 47.4 ± 1.2 % at 24 h, 34.6 ± 0.8 % at 48 h and 23.5 ± 0.5 % at 72 h and LDH method of 35.9 ± 1.5 % at 24 h, 25.4 ± 0.6 % at 48 h and 19.8 ± 2.2 % at 72 h with apoptosis of 47.3 ± 0.4 %.
Conclusion: We have found that PTX-NPs showed the cytotoxic effect on all the MDA-MB cancer cell lines and showed potent anticancer activities against MDA-MB-231 cell line via induction of apoptosis.
Export Options
About this article
Cite this article as:
Vijayan Venugopal *, Shalini Krishnan , Yugesvaran V., Yee Hui Teh , Balakrishnan Siventhiran and Palanimuthu Raj Vasanth , Effect of Paclitaxel-Loaded PLGA Nanoparticles on MDA-MB Type Cell Lines: Apoptosis and Cytotoxicity Studies, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180903110301
DOI https://dx.doi.org/10.2174/1381612824666180903110301 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
CNS & Neurological Disorders - Drug Targets Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Synthesized Drug from Medicinal Plant phytochemicals Effectively Targets ECM1 Gene Mutations in Ulcerative Colitis
Letters in Drug Design & Discovery Computer Optimization of Stealth Biodegradable Polymeric Dual-loaded Nanoparticles for Cancer Therapy Using Central Composite Face-centered Design
Pharmaceutical Nanotechnology Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets Self-Assembling Peptide Nanofibrous Hydrogel as a Versatile Drug Delivery Platform
Current Pharmaceutical Design Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience Synthesis, Characterization and Evaluation of 1,3-Bisindolyl-2-Propen-1- One Derivatives as Potent Anti-Breast Cancer Agents
Current Bioactive Compounds Rationally Designed Multitarget Agents Against Inflammation and Pain
Current Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine